Maplelane Capital’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Maplelane Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-204,981	Closed	-$6.4M	–	100
2025 Q4	$6.4M	Sell	204,981 -637,019	-76%	-$15.7M	0.23%	68
2025 Q3	$17M	Buy	+842,000	New	+$14.8M	0.41%	63
2019 Q3	–	Sell	-1	Closed	–	–	175
2019 Q2	$0	Buy	+1	New	+$12	﹤0.01%	161

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Maplelane Capital's TEVA Position: Q1 2026 in Review

Maplelane Capital sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2026, closing a stake of 204,981 shares — an estimated $6.4M sold.

Maplelane Capital first reported a position in TEVA in Q2 2019 and held it in 3 quarters. The position peaked at $17M in Q3 2025. 653 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Maplelane Capital reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2026 after selling out during the quarter.
Maplelane Capital sold 204,981 Teva Pharmaceutical Industries Limited shares in Q1 2026, an estimated $6.4M.
Maplelane Capital first reported a position in Teva Pharmaceutical Industries Limited in Q2 2019 and held it in 3 quarters.
Maplelane Capital's Teva Pharmaceutical Industries Limited position peaked at $17M in Q3 2025.
653 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2026.

Based on Maplelane Capital's 13F filing for Q1 2026, filed 14 May 2026.